% study characteristics
% need to have `\\` after caption entries, otherwise compiler hangs
% reduced font size, expanded margins, remove page numbers, footer & headers - this reduces to 3 pages instead of 4-5
% sum of n (model) = 4599; sum of relapses = 228. 

{
\newgeometry{left=1.5cm, right=1.5cm, top=2cm, bottom=1.5cm}
\captionsetup{width=1\textheight, font=scriptsize, skip=7pt}

\begin{landscape}
  % \singlespacing
  \pagestyle{empty}
  \scriptsize
  \begin{ThreePartTable}
    \begin{TableNotes}
      \item[1] Study name is composed of the lead author and year of publication or most recent protocol.
      \item[2] Contributed number of participants from KAMRC site only.
      \item[3] Amphotericin B deoxycholate arm not reported in publication.
      \item[4] Protocol not in public domain.
    \end{TableNotes}

    \begin{longtable}[c]{L{1.5cm} L{3.5cm} L{1.5cm} L{2.5cm} L{2.5cm} L{2.5cm} L{2.5cm} L{1.5cm} L{1.2cm} L{1.3cm} L{1.3cm}}
      \caption{Key characteristics of included studies, ordered by lead author and year of publication/protocol. Where information not presented in the publication, information is extracted from the study protocol. -: not reported; ABLE: Amphotericin B lipid emulsion (Bharat Serum and Vaccines Ltd.); alt: alternative; ABD: Amphotericin B deoxycholate; BMGF: Bill and Melinda Gates Foundation; BPKIHS: B.P. Koirala Institute of Health Sciences; D: Day(s); EC: European Commission; Govt.: Government; ICMR: Indian Council of Medical Research; IM: Intramuscular; KAMRC: Kala-azar Medical Research Center; LAMB: Liposomal amphotericin B (Gilead formulation unless otherwise specified); MF: Miltefosine; mg/kg: milligrams per kilogram; NCVBDC: National Center for Vector Borne Diseases Control; OD: Once daily; P: Publication; PATH: Program for Appropriate Technology in Health; PM: Paromomycin; Pr: Protocol; Ref: Reference; RMRIMS: Rajendra Memorial Research Institute of Medical Sciences; SDA: Single-dose administration; SSG: Sodium stibogluconate; TDR: UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; UN: United Nations; WHO: World Health Organization\label{tab:isc_study}} \\
      \toprule
      Study\tnote{1}                                  & Title                                                                                                                                                                                                                       & Journal                  & Sponsor/funding                                                                      & Location(s)                                       & Study design                                                                       & Study arm(s)                                                                                                                   & Age (years) & Study period & n (model)    & Relapses (\%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \\ \midrule
      \endfirsthead

      \caption[]{continued}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \\
      \toprule
      Study\tnote{1}                                  & Title                                                                                                                                                                                                                       & Journal                  & Sponsor/funding                                                                      & Location(s)                                       & Study design                                                                       & Study arm(s)                                                                                                                   & Age (years) & Study period & n (model)    & Relapses (\%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \\ \midrule
      \endhead

      \multicolumn{11}{r}{\textit{continued on next page}}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \\
      \endfoot

      \insertTableNotes
      \endlastfoot

      Bhattacharya 2007\cite{bhattacharya2007}        & Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis                                                                                                                                             & J Infect Dis             & ICMR                                                                                 & 13 locations in Bihar, India (outpatient setting) & Open label; phase 4; safety/efficacy                                               & 1: MF 28D                                                                                                                      & 2--65       & 2002--2004   & 352\tnote{2} & 22 (6.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \\ \midrule
      Chakraborty 2008\cite{chakraborty2008}          & Human placental extract offers protection against experimental visceral leishmaniasis: a pilot study for a phase-I clinical trial                                                                                           & Am J Trop Med Hyg        & Indian Council of Scientific and Industrial Research; Albert David Ltd.              & KAMRC, Muzaffarpur, India                         & ``Pre-phase 1''; pilot/preliminary                                                 & 2\tnote{3}: 2.06mg human placental extract IM, single dose (or ABD 1mg/kg alt. days for 30D)                                   & $\geq$5     & 2003--2005   & 6            & 0 (0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \\ \midrule
      Das 2009\cite{das2009}                          & A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India & Ther Clin Risk Manag     & -                                                                                    & RMRIMS, Patna, India                              & Randomised; open label; efficacy                                                   & 2: ABD 1mg/kg alt. days for 30D vs pentamidine IM 4mg/kg alt days, 30D                                                         & 6--60       & 2002         & 73           & 5 (6.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \\ \midrule
      Koirala 2003                                    & Phase IV trial of miltefosine in the treatment of visceral leishmaniasis                                                                                                                                                    & Protocol only\tnote{4}   & -                                                                                    & BPKIHS, Dharan, Nepal                             & Open label; phase 4; safety/efficacy                                               & 1: MF 28D                                                                                                                      & 2--65       & 2003--2004   & 116          & 12 (10.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              \\ \midrule
      Pandey 2016\cite{pandey2016}                    & Pharmacovigilance of miltefosine in treatment of visceral leishmaniasis in endemic areas of Bihar                                                                                                                           & Am J Trop Med Hyg        & NCVBDC, Govt. of India; World Bank                                                   & 4 locations in Bihar, India                       & Open label; safety/efficacy                                                        & 1: MF 28D                                                                                                                      & 6--70       & 2012--2015   & 600          & 45 (7.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \\ \midrule
      Pandey 2017\cite{pandey2017}                    & Efficacy and safety of liposomal amphotericin B for visceral leishmaniasis in children and adolescents at a tertiary care center in Bihar, India                                                                            & Am J Trop  Med Hyg       & -                                                                                    & RMRIMS, Patna, India                              & Open label; safety/efficacy                                                        & 1: LAMB 10mg/kg SDA                                                                                                            & $<$15       & 2014--2016   & 100          & 2 (2.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \\ \midrule
      Rijal 2003\cite{rijal2003}                      & Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline                                                                     & Trans R Soc Trop Med Hyg & WHO, Geneva University Hospital; Novartis Foundation                                 & BPKIHS, Dharan, Nepal                             & Non-randomised; efficacy                                                           & 2: SSG 20mg/kg OD, 30D either (i) in hospital or (ii) first 5--7 days in hospital; extended to 40D if positive aspirate at 30D & All         & 2000--2001   & 102          & 1 (1.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \\ \midrule
      Rijal 2010(A)\cite{rijal2010a}                  & Efficacy and safety of liposomal amphotericin B in Nepalese patients with visceral leishmaniasis                                                                                                                            & Protocol only            & TDR                                                                                  & BPKIHS, Dharan, Nepal                             & Phase 2/3; safety/efficacy                                                         & 1: LAMB, 3mg/kg OD, 5D                                                                                                         & 12--65      & 2010--2011   & 32           & 1 (3.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \\ \midrule
      Rijal 2010(B)\cite{rijal2010b}                  & Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal                                                                                                           & Trans R Soc Trop Med Hyg & EC (5th Framework Programme)                                                         & BPKIHS, Dharan, Nepal                             & Prospective cohort                                                                 & 1: SSG 20mg/kg OD, 30D                                                                                                         & -           & 2001--2003   & 178          & 1 (0.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \\ \midrule
      Sundar 2007\cite{sundar2007a,sundar2005prot}    & Injectable paromomycin for visceral leishmaniasis in India                                                                                                                                                                  & N Engl J Med             & PATH (including UN, BMGF, TDR)                                                       & 4 locations in Bihar, India                       & Randomised; open label; phase 3; non-inferiority; safety/efficacy                  & 2: PM 15mg/kg IM, 21D vs. ABD 1mg/kg alt. days, 30D                                                                            & 5--55       & 2003--2004   & 250\tnote{2} & 4 (1.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \\ \midrule
      Sundar 2008(A)\cite{sundar2008protC,sundar2008} & New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine                                                                                     & Clin Infect Dis          & Banaras Hindu University                                                             & KAMRC, Muzaffarpur, India                         & Partially randomised; open label; phase 2; non-comparative; sequential; triangular & 5: LAMB 5mg/kg SD alone, or comb. LAMB 3.75--5mg/kg SD + MF 7--14D                                                             & $\geq$12    & 2006--2007   & 225          & 7 (3.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \\ \midrule
      Sundar 2008(B)\cite{sundar2008B}                & Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian kala-azar                                                                                                                              & Trop Med Int Health      & Bharat Serum and Vaccines Ltd.                                                       & KAMRC, Muzaffarpur, India                         & Non-randomised; non-comparative; open label; phase 2; safety/efficacy              & 3: ABLE OD for 3D at (i) 5mg/kg (ii) 4mg/kg (iii) 3mg/kg                                                                       & 12--65      & 2004--2005   & 45           & 4 (8.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \\ \midrule
      Sundar 2009\cite{sundar2008protB, sundar2009}   & Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment                                                                                                                           & Clin Infect Dis          & Banaras Hindu University                                                             & KAMRC, Muzaffarpur, India                         & Randomised; open label; phase 3; safety/efficacy                                   & 2: PM OD 15mg/kg/day for either (i) 21D or (ii) 14D                                                                            & 5--55       & 2007--2008   & 307          & 26 (8.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \\ \midrule
      Sundar 2010\cite{sundar2008protA, sundar2010}   & Single-dose liposomal amphotericin B for visceral leishmaniasis in India                                                                                                                                                    & N Engl J Med             & Banaras Hindu University                                                             & KAMRC, Muzaffarpur, India                         & Randomised; open label; phase 3; safety/efficacy                                   & 2: ABD 1mg/kg alt. days for 30D, vs. LAMB 10mg/kg SDA                                                                          & 2--65       & 2008--2009   & 412          & 14 (3.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \\ \midrule
      Sundar 2011\cite{sundar2006prot,sundar2011}     & Ambisome plus miltefosine for Indian patients with kala-azar                                                                                                                                                                & Trans R Soc Trop Med Hyg & Banaras Hindu University                                                             & KAMRC, Muzaffarpur; RMRIMS, Patna, India          & Open label; phase 2; safety/efficacy                                               & 1: LAMB 5mg/kg SDA followed by MF D2-D15                                                                                       & 2--65       & 2007--2009   & 128          & 5 (3.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \\ \midrule
      Sundar 2012\cite{sundar2012}                    & Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use                                                                                                                           & Clin Infect Dis          & EC (Kaladrug-R); Sitaram Memorial Trust                                              & KAMRC, Muzaffarpur, India                         & Open label; safety/efficacy                                                        & 1: MF 28D                                                                                                                      & 6--70       & 2009--2010   & 571          & 34 (6.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \\ \midrule
      Sundar 2014\cite{sundar2009prot, sundar2014}    & Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomised, open-label study                                                                  & PLoS Negl Trop Dis       & Bharat Serums and Vaccines Ltd; Department of Science and Technology, Govt. of India & 4 locations in Bihar, India.                      & Randomised; open label; phase 3; safety/efficacy                                   & 2: LAMB 15mg/kg SDA vs. ABLE 15mg/kg SDA                                                                                       & 5--65       & 2009--2011   & 144\tnote{2} & 9 (6.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \\ \midrule
      Sundar 2015\cite{sundar2011prot,sundar2015}     & Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: A phase 2 study                                                                                                          & Am J Trop Med Hyg        & Lifecare Innovations; Department of Science and Technology, Govt. of India           & KAMRC, Muzaffarpur, India                         & Non-randomised; non-comparative; open label; phase 2; safety/efficacy              & 2: LAMB (Lifecare Innovations) 10mg/kg SDA vs. 15mg/kg SDA                                                                     & 12--60      & 2012--2013   & 30           & 3 (10.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \\ \midrule
      Sundar 2019\cite{sundar2012prot,sundar2019}     & Effectiveness of single-dose liposomal amphotericin B in visceral leishmaniasis in Bihar                                                                                                                                    & Am J Trop Med Hyg        & Banaras Hindu University                                                             & KAMRC, Muzaffarpur, India                         & Observational; efficacy                                                            & 1: LAMB 10mg/kg SDA                                                                                                            & All         & 2013--2017   & 928          & 33 (3.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \\ \bottomrule
    \end{longtable}
  \end{ThreePartTable}
\end{landscape}
}
\pagestyle{fancy}
\restoregeometry